Preinfusion fVIII antigen, fVIII activity, and anti-fVIII Ab determination in 7 hemophilia A subjects on different phlebotomy dates (cycles)
| Subject ID and cycle . | fVIII antigen, pM . | fVIII activity, pM . | fVIII antibody, nM . | fVIII product infused . |
|---|---|---|---|---|
| Subject 26 | ||||
| Cycle 1 | 2.6 ± 0.4 | 1.5 ± 0.7 | 1.1 ± 0.1 | A |
| Cycle 2 | 13.6 ± 2.4 | 1.2 ± 0.1 | 4.0 ± 0.07 | B |
| Cycle 3 | ND | 4.5 ± 0.1 | 5.1 ± 0.9 | C |
| Cycle 4 | ND | 5.7 ± 0.4 | 4.0 ± 0.3 | D |
| Cycle 5 | 37.8 ± 4.6 | 10.7 ± 0 | 17.6 ± 0.4 | E |
| Subject 27 | ||||
| Cycle 1 | 45.0 ± 0.2 | 2.5 ± 0.4 | 0.5 ± 0.3 | B |
| Cycle 2 | 75.9 ± 2.2 | 1.9 ± 0.05 | ND | C |
| Cycle 3 | 96.4 ± 17.7 | 28.7 ± 0 | 2.5 ± 2.3 | D |
| Cycle 4 | 116.7 ± 28.5 | 13.6 ± 1.6 | 3.2 ± 2.0 | E |
| Cycle 5 | 109.8 ± 16.1 | 7.1 ± 0.7 | 2.0 ± 0.3 | A |
| Subject 28 | ||||
| Cycle 1 | ND | ND | 0.6 ± 0.2 | C |
| Cycle 2 | ND | 1.6 ± 0.2 | 2.4 ± 0.2 | D |
| Cycle 3 | ND | 57.6 ± 2.3 | ND | E |
| Cycle 4 | 37.8 ± 4.6 | 7.0 ± 1.5 | ND | A |
| Cycle 5 | 12.9 ± 0.6 | 5.2 ± 0.9 | ND | B |
| Subject 29 | ||||
| Cycle 1 | 13.0 ± 3.0 | ND | ND | B |
| Cycle 2 | 64.8 ± 11.7 | 1.3 ± 0.1 | ND | B |
| Cycle 3 | 30.4 ± 6.1 | 4.5 ± 0.5 | 2.5 ± 2.1 | B |
| Subject 30 | ||||
| Cycle 1 | ND | ND | 4.6 ± 0.2 | B |
| Cycle 2 | 39.9 ± 12.6 | 70.5 ± 2.9 | 3.1 ± 1.9 | B |
| Cycle 3 | ND | 0.6 ± 0.03 | 3.5 ± 0.8 | B |
| Subject 31 | ||||
| Cycle 1 | 20.0 ± 2.0 | 1.4 ± 0.3 | ND | D |
| Cycle 2 | 91.7 ± 5.4 | 9.7 ± 1.3 | ND | E |
| Cycle 3 | 31.0 ± 7.3 | 2.7 ± 0.05 | ND | A |
| Cycle 4 | 114.7 ± 12.5 | 6.8 ± 1.2 | ND | B |
| Cycle 5 | 121.1 ± 17.3 | 6.0 ± 0 | ND | C |
| Subject 32 | ||||
| Cycle 1 | 13.0 ± 3.0 | ND | ND | B |
| Cycle 2 | 64.8 ± 11.7 | 1.3 ± 0.1 | ND | B |
| Cycle 3 | 30.4 ± 6.1 | 4.5 ± 0.5 | ND | B |
| Subject ID and cycle . | fVIII antigen, pM . | fVIII activity, pM . | fVIII antibody, nM . | fVIII product infused . |
|---|---|---|---|---|
| Subject 26 | ||||
| Cycle 1 | 2.6 ± 0.4 | 1.5 ± 0.7 | 1.1 ± 0.1 | A |
| Cycle 2 | 13.6 ± 2.4 | 1.2 ± 0.1 | 4.0 ± 0.07 | B |
| Cycle 3 | ND | 4.5 ± 0.1 | 5.1 ± 0.9 | C |
| Cycle 4 | ND | 5.7 ± 0.4 | 4.0 ± 0.3 | D |
| Cycle 5 | 37.8 ± 4.6 | 10.7 ± 0 | 17.6 ± 0.4 | E |
| Subject 27 | ||||
| Cycle 1 | 45.0 ± 0.2 | 2.5 ± 0.4 | 0.5 ± 0.3 | B |
| Cycle 2 | 75.9 ± 2.2 | 1.9 ± 0.05 | ND | C |
| Cycle 3 | 96.4 ± 17.7 | 28.7 ± 0 | 2.5 ± 2.3 | D |
| Cycle 4 | 116.7 ± 28.5 | 13.6 ± 1.6 | 3.2 ± 2.0 | E |
| Cycle 5 | 109.8 ± 16.1 | 7.1 ± 0.7 | 2.0 ± 0.3 | A |
| Subject 28 | ||||
| Cycle 1 | ND | ND | 0.6 ± 0.2 | C |
| Cycle 2 | ND | 1.6 ± 0.2 | 2.4 ± 0.2 | D |
| Cycle 3 | ND | 57.6 ± 2.3 | ND | E |
| Cycle 4 | 37.8 ± 4.6 | 7.0 ± 1.5 | ND | A |
| Cycle 5 | 12.9 ± 0.6 | 5.2 ± 0.9 | ND | B |
| Subject 29 | ||||
| Cycle 1 | 13.0 ± 3.0 | ND | ND | B |
| Cycle 2 | 64.8 ± 11.7 | 1.3 ± 0.1 | ND | B |
| Cycle 3 | 30.4 ± 6.1 | 4.5 ± 0.5 | 2.5 ± 2.1 | B |
| Subject 30 | ||||
| Cycle 1 | ND | ND | 4.6 ± 0.2 | B |
| Cycle 2 | 39.9 ± 12.6 | 70.5 ± 2.9 | 3.1 ± 1.9 | B |
| Cycle 3 | ND | 0.6 ± 0.03 | 3.5 ± 0.8 | B |
| Subject 31 | ||||
| Cycle 1 | 20.0 ± 2.0 | 1.4 ± 0.3 | ND | D |
| Cycle 2 | 91.7 ± 5.4 | 9.7 ± 1.3 | ND | E |
| Cycle 3 | 31.0 ± 7.3 | 2.7 ± 0.05 | ND | A |
| Cycle 4 | 114.7 ± 12.5 | 6.8 ± 1.2 | ND | B |
| Cycle 5 | 121.1 ± 17.3 | 6.0 ± 0 | ND | C |
| Subject 32 | ||||
| Cycle 1 | 13.0 ± 3.0 | ND | ND | B |
| Cycle 2 | 64.8 ± 11.7 | 1.3 ± 0.1 | ND | B |
| Cycle 3 | 30.4 ± 6.1 | 4.5 ± 0.5 | ND | B |
Cycle indicates therapeutic intervention; and ND, not detectable.